We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Agreement Will Hasten Development of Alzheimer's Disease Diagnostic Test

By LabMedica International staff writers
Posted on 16 Dec 2009
The availability of an Alzheimer's disease (AD) test targeted to the protein p97 will enable earlier diagnosis, quantitative disease monitoring, and better patient outcomes. More...
The p97 protein is a secreted protein specifically expressed by amyloid plaque-associated reactive microglia.

biOasis Technologies Inc. (South Surrey, BC, Canada) announced that a major step in the application of its p97 test for diagnosis of Alzheimer's disease was achieved by the signing of an agreement with UK-based Fleet Bioprocessing Ltd. (Fleet; Hartley Whitney, UK).

Rob Hutchison, CEO, biOasis commented, ''If earlier diagnosis and improved patient management result in delaying the average onset of the disease by even one-year, society would save in excess of U.S. $12 billion annually. The agreement with Fleet will reduce product development timelines for the biOasis p97 Alzheimer's test and enable faster entry into the $36 billion IVD market."

Fleet Bioprocessing are expert providers of high-quality contract development and manufacturing services. They meet the needs of the diagnostics, pharma, and biotech sectors, offering a range of services from purification and conjugation of proteins, through to immunoassay development and the formulation and dispensing of reagents.

biOasis Technologies Inc. is a company focused on the Health Care & Life Sciences market, and is engaged in the development and commercialization of diagnostics and therapeutic delivery systems related to neurological diseases.

Related Links:
biOasis Technologies Inc.
Fleet Bioprocessing Ltd.



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.